Skip to main content

Table 6 Risk of fracture associated with different types of ADT

From: Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

  Adjusted OR (95 % CI) any fracturea Adjusted OR (95 % CI) accidental fracturea Adjusted OR (95 % CI) hip fracturea
No ADT 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
GnRH agonists + anti-androgens 3.48 (3.07–3.96) 1.60 (1.36–1.88) 1.82 (1.39–2.38)
GnRH agonist only 1.33 (1.09–1.63) 1.17 (0.93–1.47) 1.70 (1.19–2.42)
Anti-androgen only 2.11 (1.72–2.59) 1.37 (1.07–1.77) 1.81 (1.24–2.63)
Orchiectomy alone 2.54 (1.76–3.66) 2.18 (1.43–3.33) 1.88 (0.96–3.67)
Orchiectomy + pharmacologic ADT 4.32 (3.34–5.58) 1.39 (0.93–2.07) 1.59 (0.86–2.93)
  1. ADT androgen deprivation therapy, GnRH gonadotropin-releasing hormone, OR odds ratio, CI confidence interval
  2. aAdjusted for age at diagnosis and ethnicity
  3. Bold indicate significant p-value (<0.5)